Travis Whitfill
Founder at AZITRA, INC.
Net worth: 73 590 $ as of 2024-04-29
Profile
Travis Whitfill is the founder of Azitra, Inc. (founded in 2014) where he holds the title of Chief Operating Officer & Director.
He is currently working as an Independent Director at IN8bio, Inc. (since 2018) and as a Partner at BIOS Equity Partners LP (since 2015).
Mr. Whitfill has previously worked as a Director at 410 Medical, Inc. (2017-2019), as a Director at Immusoft Corp., as a Director at SIRPant Immunotherapeutics, Inc. (2021-2023), and as a Partner at BIOS Capital Management LP (2015-2023).
Mr. Whitfill has an undergraduate degree from Dallas Baptist University and graduate degrees from Yale University and University College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AZITRA INC
1.16% | 2024-02-12 | 334,500 ( 1.16% ) | 73 590 $ | 2024-04-29 |
Travis Whitfill active positions
| Companies | Position | Start |
|---|---|---|
| AZITRA, INC. | Founder | 2014-01-01 |
| IN8BIO, INC. | Director/Board Member | 2018-05-06 |
BIOS Equity Partners LP
 BIOS Equity Partners LP Investment ManagersFinance Part of BIOS Capital Management LP, BIOS Equity Partners LP functions as a private equity firm. The company is based in Texas. The American company was founded by Leslie W. Kreis. | Corporate Officer/Principal | 2015-09-30 |
Former positions of Travis Whitfill
| Companies | Position | End |
|---|---|---|
BIOS Capital Management LP
 BIOS Capital Management LP Investment ManagersFinance BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas. | Private Equity Investor | 2023-05-31 |
SIRPant Immunotherapeutics, Inc.
 SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Director/Board Member | 2023-05-31 |
410 Medical, Inc.
 410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Director/Board Member | 2019-06-30 |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Director/Board Member | - |
Training of Travis Whitfill
| Dallas Baptist University | Undergraduate Degree |
| Yale University | Graduate Degree |
| University College London | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AZITRA, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Health Technology |
BIOS Capital Management LP
BIOS Capital Management LP Investment ManagersFinance BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas. | Finance |
BIOS Equity Partners LP
BIOS Equity Partners LP Investment ManagersFinance Part of BIOS Capital Management LP, BIOS Equity Partners LP functions as a private equity firm. The company is based in Texas. The American company was founded by Leslie W. Kreis. | Finance |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Health Technology |
- Stock Market
- Insiders
- Travis Whitfill
